## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.3% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.88)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Acadia Pharmaceuticals stock price target raised by Stifel to $25 from $24**
- Source: Investing.com UK | 20251211T131009 | Somewhat-Bullish | Relevance: 97%
- Stifel has increased its price target for Acadia Pharmaceuticals (NASDAQ:ACAD) to $25.00 from $24.00, maintaining a Hold rating despite the company's strong year-to-date performance and recent intellectual property victory for Nuplazid. The firm indicates that Acadia's future stock performance largely depends on renewed growth from its Daybue product or positive Phase 2 data for ACP-204 in Alzheimerâ€™s disease psychosis, expected in mid-2026. InvestingPro analysis suggests the stock is currently undervalued, with a PEG ratio of 0.18.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Stifel | $25 | $24 | +4% |
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Stifel | main | Hold |
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 4 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (2 raises, avg +12%). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 32.9 |
| Current P/E | 32.7 |
| YoY Growth | -0.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 7.2% to 1.3% (-5.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.7pp (needs >3.0% for momentum thesis). MRS_5 (-0.9%) diverging from MRS_10 - short-term weakness emerging. Outperforming sector by 3.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.30% (CS: 52) | Neutral |
| RSI_14 | 67.0 | Neutral |
| MACD Histogram | 0.16 | Bullish |
| vs SMA20 | 1.066x | Above |
| vs SMA50 | 1.156x | Above |
| vs SMA200 | 1.257x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $26.68
- **Stop Loss:** $24.88 (6.7% risk)
- **Target:** $28.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 766
- **Position Value:** $20,436.88
- **Portfolio %:** 20.44%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*